Free Trial

Revelation Biosciences (REVBW) 10K Form and Latest SEC Filings 2026

$0.0075 0.00 (-10.74%)
As of 03:23 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Revelation Biosciences SEC Filings & Recent Activity

Revelation Biosciences (NASDAQ:REVBW) has submitted 197+ documents to the U.S. Securities and Exchange Commission (SEC) since 2020. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 4 submitted on May 1, 2026.

Form 4
REVELATION BIOSCIENCES, INC. Reports Ownership Change on May. 1, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

10-Q
Revelation Biosciences Files Quarterly Report on Nov. 8, 2024

The 10-Q contains Revelation Biosciences's unaudited quarterly financial statements, revenue, earnings updates, and cash flow changes between annual reports.

View earnings history

Revelation Biosciences SEC Filing History

Browse Revelation Biosciences' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/01/2026 4:31 PM
Revelation Biosciences (1810560) Issuer
Zygmont Chester Stanley III (1900657) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/01/2026 4:32 PM
Revelation Biosciences (1810560) Issuer
Rolke James (1693858) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/30/2026 3:31 PM
Revelation Biosciences (1810560) Filer
Form PRE 14A
04/15/2026 3:13 PM
Revelation Biosciences (1810560) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/17/2026 8:37 PM
ARMISTICE CAPITAL, LLC (1601086) Filed by
Revelation Biosciences (1810560) Subject
Form SCHEDULE 13G/A
02/17/2026 11:35 AM
Revelation Biosciences (1810560) Filer
Form DEF 14A
02/11/2026 11:15 PM
Revelation Biosciences (1810560) Filer
Form EFFECT
02/11/2026 4:30 PM
Revelation Biosciences (1810560) Filer
Form 424B3
02/05/2026 4:29 PM
Revelation Biosciences (1810560) Issuer
Zygmont Chester Stanley III (1900657) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 4:29 PM
Revelation Biosciences (1810560) Issuer
Rolke James (1693858) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 4:30 PM
CARVER JENNIFER (1663163) Reporting
Revelation Biosciences (1810560) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 4:30 PM
Chawla Lakhmir S (1646626) Reporting
Revelation Biosciences (1810560) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
02/05/2026 4:31 PM
Revelation Biosciences (1810560) Issuer
ROPER JESS (1408993) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/20/2026 7:31 PM
Revelation Biosciences (1810560) Subject
SABBY MANAGEMENT, LLC (1535610) Filed by
Form SCHEDULE 13G
01/12/2026 4:21 PM
Revelation Biosciences (1810560) Issuer
Rolke James (1693858) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 4:12 PM
CARVER JENNIFER (1663163) Reporting
Revelation Biosciences (1810560) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 4:17 PM
Revelation Biosciences (1810560) Issuer
Zygmont Chester Stanley III (1900657) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 4:08 PM
Revelation Biosciences (1810560) Issuer
ROPER JESS (1408993) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/12/2026 4:01 PM
Chawla Lakhmir S (1646626) Reporting
Revelation Biosciences (1810560) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
12/03/2025 4:01 PM
Revelation Biosciences (1810560) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2025 5:15 PM
ARMISTICE CAPITAL, LLC (1601086) Filed by
Revelation Biosciences (1810560) Subject
Form SCHEDULE 13G
11/12/2025 3:10 PM
Revelation Biosciences (1810560) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
11/10/2025 1:57 PM
Revelation Biosciences (1810560) Filer
Form DEF 14A
10/31/2025 11:54 AM
Revelation Biosciences (1810560) Issuer
ROPER JESS (1408993) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/31/2025 11:55 AM
Revelation Biosciences (1810560) Issuer
Zygmont Chester Stanley III (1900657) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/31/2025 11:56 AM
CARVER JENNIFER (1663163) Reporting
Revelation Biosciences (1810560) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/31/2025 11:58 AM
Revelation Biosciences (1810560) Issuer
Rolke James (1693858) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/31/2025 12:01 PM
Chawla Lakhmir S (1646626) Reporting
Revelation Biosciences (1810560) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/31/2025 8:19 AM
Revelation Biosciences (1810560) Filer
Form PRE 14A
10/15/2025 4:06 PM
Revelation Biosciences (1810560) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/30/2025 11:15 PM
Revelation Biosciences (1810560) Filer
Form EFFECT
09/30/2025 4:13 PM
Revelation Biosciences (1810560) Filer
Form 424B3
09/22/2025 3:15 PM
Revelation Biosciences (1810560) Filer
Form DEF 14A
09/16/2025 4:18 PM
Revelation Biosciences (1810560) Filer
Form S-3
Registration statement under Securities Act of 1933  
09/15/2025 4:02 PM
Revelation Biosciences (1810560) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/12/2025 3:08 PM
Revelation Biosciences (1810560) Filer
Form PRE 14A
09/09/2025 7:02 AM
Revelation Biosciences (1810560) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/08/2025 7:10 AM
Revelation Biosciences (1810560) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/25/2025 3:26 PM
Revelation Biosciences (1810560) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/09/2025 3:51 PM
Revelation Biosciences (1810560) Filer
Form DEF 14A
06/04/2025 3:05 PM
Revelation Biosciences (1810560) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/29/2025 8:44 AM
Revelation Biosciences (1810560) Filer
Form 424B3
05/28/2025 11:15 PM
Revelation Biosciences (1810560) Filer
Form EFFECT
05/23/2025 8:56 AM
Revelation Biosciences (1810560) Filer
Form S-1/A
05/20/2025 1:20 PM
Revelation Biosciences (1810560) Filer
Form S-1
Registration statement under Securities Act of 1933  
(Data available from 1/1/2016 forward)

Revelation Biosciences SEC Filings - Frequently Asked Questions

Revelation Biosciences (REVBW) has submitted 197+ filings to the SEC since 2020. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form 4 submitted on May 1, 2026. This was an insider ownership change filed by 4 - REVELATION BIOSCIENCES, INC. (0001810560) (Issuer).

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:REVBW) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners